ES2173945T3 - Uso de antagonistas de aldosterona para inhibir fibrosis miocardiaca. - Google Patents

Uso de antagonistas de aldosterona para inhibir fibrosis miocardiaca.

Info

Publication number
ES2173945T3
ES2173945T3 ES95903131T ES95903131T ES2173945T3 ES 2173945 T3 ES2173945 T3 ES 2173945T3 ES 95903131 T ES95903131 T ES 95903131T ES 95903131 T ES95903131 T ES 95903131T ES 2173945 T3 ES2173945 T3 ES 2173945T3
Authority
ES
Spain
Prior art keywords
inhibit
miocardiac
fibrosis
aldosterone antagonists
aldosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95903131T
Other languages
English (en)
Inventor
Karl T Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Missouri-Columbia
Original Assignee
University of Missouri-Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Missouri-Columbia filed Critical University of Missouri-Columbia
Application granted granted Critical
Publication of ES2173945T3 publication Critical patent/ES2173945T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION DESCRIBE UN METODO DE UTILIZACION DE UN ANTAGONISTA DE ALDOESTERONA COMO ESPIRONOLACTONA Y EPOXIMEXRENONA, EN UNA DOSIFICACION QUE NO INTERRUMPE EL EQUILIBRIO DE ELECTROLITO Y RETENCION DE AGUA NORMAL DE UN PACIENTE, PARA INHIBIR FIBROSIS MIOCARDIACA, INCLUYENDO HIPERTROFIA DEL VENTRICULO IZQUIERDO (LVH).
ES95903131T 1993-12-02 1994-12-01 Uso de antagonistas de aldosterona para inhibir fibrosis miocardiaca. Expired - Lifetime ES2173945T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/160,236 US5529992A (en) 1992-04-21 1993-12-02 Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors

Publications (1)

Publication Number Publication Date
ES2173945T3 true ES2173945T3 (es) 2002-11-01

Family

ID=22576080

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95903131T Expired - Lifetime ES2173945T3 (es) 1993-12-02 1994-12-01 Uso de antagonistas de aldosterona para inhibir fibrosis miocardiaca.

Country Status (9)

Country Link
US (3) US5529992A (es)
EP (1) EP0730458B1 (es)
JP (1) JP2916267B2 (es)
AT (1) ATE214607T1 (es)
AU (1) AU703147B2 (es)
CA (1) CA2177848A1 (es)
DE (1) DE69430209T2 (es)
ES (1) ES2173945T3 (es)
WO (1) WO1995015166A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6008210A (en) * 1992-04-21 1999-12-28 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
AU5982296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone
AU6039296A (en) 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
CN1142793C (zh) * 1995-06-07 2004-03-24 G·D·瑟尔公司 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
AU6158096A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failure
AU5349400A (en) * 1995-06-07 2000-10-26 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
ATE370738T1 (de) * 1999-11-09 2007-09-15 Pharmacia Corp Verwendung von eplerenon zur behandlung von restenose
WO2001041770A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Nanoparticulate eplerenone compositions
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
JP3566940B2 (ja) * 2000-04-18 2004-09-15 古河電気工業株式会社 アレイ導波路回折格子型光合分波器
WO2001087284A2 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
EP1368009A2 (en) * 2000-07-27 2003-12-10 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
ITMI20010821A1 (it) * 2001-04-17 2002-10-17 Gienne Pharma S P A Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco
WO2003049745A1 (en) 2001-12-12 2003-06-19 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
JP2006508174A (ja) * 2002-01-25 2006-03-09 ファルマシア・コーポレーション 炎症関連疾患を予防または治療するためのアルドステロンブロッカー療法
EP1469862A2 (en) * 2002-01-30 2004-10-27 Pharmacia Corporation Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
US20040102375A1 (en) * 2002-05-15 2004-05-27 Massachusetts Institute Of Technology Methods to overcome inhibition of growth cone translocation
ES2270143T3 (es) * 2002-08-07 2007-04-01 Novartis Ag Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona.
MXPA05002062A (es) * 2002-08-23 2005-06-08 Pharmacia Corp Modulacion de la actividad de la metaloproteinasa de la matriz con bloqueador(es) de aldosterona.
WO2004041289A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
ES2305520T3 (es) * 2002-11-18 2008-11-01 Novartis Ag Derivados de imidazo(1,5a)piridina y metodos para tratar enfermedades mediadas por aldosterona.
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
AU2007217980A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
WO2007139992A2 (en) * 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008027284A1 (en) * 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
WO2009097893A1 (en) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
JP6273072B2 (ja) * 2014-05-16 2018-01-31 カンバーランド ファーマシューティカルズ，インコーポレーテッド イフェトロバンにより心臓線維症を治療する組成物及び方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003996A (en) * 1974-09-09 1977-01-18 G. D. Searle & Co. Spirolactone for inhibiting the cardiotoxic effects of adriamycin

Also Published As

Publication number Publication date
AU703147B2 (en) 1999-03-18
EP0730458A1 (en) 1996-09-11
US5668125A (en) 1997-09-16
DE69430209D1 (de) 2002-04-25
US5668124A (en) 1997-09-16
US5529992A (en) 1996-06-25
JPH09508354A (ja) 1997-08-26
AU1210695A (en) 1995-06-19
CA2177848A1 (en) 1995-06-08
JP2916267B2 (ja) 1999-07-05
WO1995015166A1 (en) 1995-06-08
EP0730458B1 (en) 2002-03-20
DE69430209T2 (de) 2002-12-12
ATE214607T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
ES2144989T1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c como agente, o co-agente, de disgregacion.
PT735882E (pt) Combinacao contraceptiva contendo antagonistas de progesterona e um progestogeno
ES2133130B1 (es) Nueva formulacion de budesonida, su uso y recipiente que la contiene.
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
BR0101332A (pt) Formulação oftálmica tópica na forma de uma solução aquosa, e, uso de uma ciclosporina em associação com ácido hialurÈnico ou um de seus sais e com polisorbato 80
DE60124240D1 (de) Pyrophosphate zur erhöhung der zellfunktion durch schutz von muscarinrezeptoren
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
HUP9701560A1 (hu) "Olaj a vízben"típusú topikális alkalmazású folyékony emulzió készítmény
DE59904887D1 (de) Vorrichtung zur abgabe von wirkstoffen in das spülwasser, insbesondere in toilettenbecken
GT199800136A (es) Formas de dosificacion farmaceuticas solidas.
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
ES2176421T3 (es) Composicion topica gelificada estable que contiene un electrolito, un agente activo y etil hidroxietilcelulosa.
PT1175224E (pt) Terapeutica de combinacao contra hiv com interferao-alfa peguilado e um antagonista de ccr5
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
ES2195382T3 (es) Compuestos indolcarboxilicos y su uso como compuestos farmaceuticos.
ATE214607T1 (de) Verwendung von aldosteronantagonisten zur hemmung von myocardfibrose
ECSP045025A (es) Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
PT706385E (pt) Utilizacao de isovaleramida como agente ansiolitico suave e como agente sedativo suave
BR9909486A (pt) Compostos calcilìticos
UY28007A1 (es) Tratamiento terapeutico
ES2169763T3 (es) Derivados de pirimidinona.
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
UY28017A1 (es) Tratamiento terapéutico
ES2129563T3 (es) Empleo de una combinacion de un inhibidor de la enzima convertidora de angiotensina y un antagonista del calcio para el tratamiento de una proteinuria.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730458

Country of ref document: ES